Table 1.

CML dendritic cells are selectively endowed with NK cell stimulatory capacities

PatientsTreatmentDisease phaseCD83 * (%)Mixed lymphocyte reactions (CML dendritic cells/normal dendritic cells)Lysis of K562 (CML dendritic cells + NK)/(normal dendritic cells + NK)Lysis of DAUDI (CML dendritic cells + NK)/(normal dendritic cells + NK)
1IFNαChronic6NDND20
2HydroxyureaAccelerated22NDND10
30Chronic300.72.18ND
40Chronic30.731.89ND
5HydroxyureaChronic50.721.63ND
60Chronic10.791.15ND
7HydroxyureaChronic0.80.731.25ND
80Chronic20.725.12ND
9PipobromanChronic2.50.831.18ND
100Chronic4.50.924.72ND
110Accelerated0.711.88ND
120Chronic26.61.14.30ND
130Chronic6.41.150.79ND
140Chronic191.151.32ND
15HydroxyureaChronic501.521.52ND
16HydroxyureaChronic10.31.421.07ND
170Chronic2.72.42.30ND
  • Abbreviation: ND, not determined.

  • * CD83 expression was determined on CML dendritic cells in flow cytometry.

  • The CML dendritic cell and normal dendritic cell capacities to activate allogeneic T cells and NK cells were compared. The ratio of proliferation between allogeneic T cells exposed to normal dendritic cells or CML dendritic cells at a stimulator/effector ratio of 1:25 is shown (mixed lymphocyte reaction column). The ratio of specific lysis against K562 or DAUDI of allogeneic NK cells stimulated with normal dendritic cells or CML dendritic cells at 20:1 effector/target ratio is depicted. CML dendritic cell and normal dendritic cell capacities to activate allogeneic T cells were comparable (P > 0.05, Student's t test), but CML dendritic cell capacity to activate allogeneic NK cells was superior to normal dendritic cells (P < 0.05).